Initial Results from the SAPHIRE Study: a Phase II Trial with the Novel Oral Histone Deacetylase (HDAC) Inhibitor Resminostat in Relapsed or Refractory Hodgkin Lymphoma Patients

Speaker

Jan Walewski

Session

New drugs